CRBP Stock Analysis: Buy, Sell, or Hold?
CRBP - Corbus Pharmaceuticals Holdings, Inc.
$7.78
0.08 (1.04%)
▲
5d:
-2.87%
30d:
-31.93%
90d:
-18.87%
BUY
MODERATE Confidence
Analysis Updated: Jun 11, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When CRBP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CRBP shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CRBP shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CRBP is currently trading at $7.78, which is considered slightly low relative to its 30-day fair value range of $7.73 to $11.10.
Technical Outlook: Technically, CRBP is in a uptrend. Immediate support is located at $7.12, while resistance sits at $8.28.
Market Sentiment: CRBP has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $36.50 (+369.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRBP is in a uptrend. Immediate support is located at $7.12, while resistance sits at $8.28.
Market Sentiment: CRBP has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $36.50 (+369.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$7.73 -
$11.10
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 369.2% below Wall St target ($36.50)
Trading Range Analysis
30-Day Trading Range
$7.73 -
$11.10
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.73
(9.3%)
Support & Resistance Levels
Support Level
$7.12
Resistance Level
$8.28
Current Trend
Uptrend
Technical data as of
Jun 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.53
Wall Street Target
$36.50
(+369.2%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: June 11, 2026 7:09 PM ET
Data refreshes hourly during market hours. Next update: 8:09 PM
Data refreshes hourly during market hours. Next update: 8:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRBP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Dominic Smethurst
SELL
3285 shares
2026-02-03
Ian Hodgson
SELL
2415 shares
2026-02-03
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 49 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 47 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 61 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$103 | 58 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 60 HOLD |
